Impaired activation of plasmacytoid dendritic cells
TGF-β
cGAS-STING
glycolysis
interferon
melanoma
plasmacytoid dendritic cells
toll-like receptor
tumor microenvironment
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
23
05
2023
accepted:
04
12
2023
medline:
22
1
2024
pubmed:
19
1
2024
entrez:
19
1
2024
Statut:
epublish
Résumé
Plasmacytoid dendritic cells (pDCs) infiltrate a large set of human cancers. Interferon alpha (IFN-α) produced by pDCs induces growth arrest and apoptosis in tumor cells and modulates innate and adaptive immune cells involved in anti-cancer immunity. Moreover, effector molecules exert tumor cell killing. However, the activation state and clinical relevance of pDCs infiltration in cancer is still largely controversial. In Primary Cutaneous Melanoma (PCM), pDCs density decreases over disease progression and collapses in metastatic melanoma (MM). Moreover, the residual circulating pDC compartment is defective in IFN-α production. The activation of tumor-associated pDCs was evaluated by Based on a set of microscopic, functional and These findings propose a new window of intervention for novel immunotherapy approaches to amplify the antitumor innate immune response in cutaneous melanoma (CM).
Identifiants
pubmed: 38239354
doi: 10.3389/fimmu.2023.1227648
pmc: PMC10795195
doi:
Substances chimiques
Cytokines
0
Toll-Like Receptor 7
0
Toll-Like Receptor 9
0
Interferon-alpha
0
Immunosuppressive Agents
0
Nucleotidyltransferases
EC 2.7.7.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1227648Informations de copyright
Copyright © 2024 Monti, Ferrari, Grosso, Missale, Bugatti, Cancila, Zini, Segala, La Via, Consoli, Orlandi, Valerio, Tripodo, Rossato and Vermi.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer CM declared a shared affiliation with the authors VG, MO and MR to the handling editor at time of review.
Références
Cell Rep. 2015 May 19;11(7):1018-30
pubmed: 25959818
Trends Immunol. 2013 Feb;34(2):67-73
pubmed: 23122052
Cancer Immunol Res. 2013 Dec;1(6):402-15
pubmed: 24778133
Cytokine. 2016 Jan;77:245-7
pubmed: 26315534
Proc Natl Acad Sci U S A. 2021 Apr 13;118(15):
pubmed: 33827917
Cancer Immunol Res. 2017 Nov;5(11):969-977
pubmed: 28935649
PLoS Comput Biol. 2013;9(8):e1003118
pubmed: 23950696
Proc Natl Acad Sci U S A. 2019 Jun 18;116(25):12410-12415
pubmed: 31152140
J Exp Med. 2007 Jun 11;204(6):1441-51
pubmed: 17535975
J Immunol. 2012 Feb 15;188(4):1583-91
pubmed: 22231699
Cancer Res. 2011 Aug 15;71(16):5423-34
pubmed: 21697280
Front Oncol. 2022 Aug 29;12:971959
pubmed: 36106115
Cancer Res. 2018 Jun 1;78(11):3014-3026
pubmed: 29523540
Lancet Oncol. 2021 May;22(5):643-654
pubmed: 33857412
Pigment Cell Melanoma Res. 2008 Apr;21(2):123-32
pubmed: 18426405
J Immunol. 2012 Sep 15;189(6):2735-45
pubmed: 22891284
Clin Cancer Res. 2023 Feb 1;29(3):667-683
pubmed: 36449659
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Oncoimmunology. 2020 Apr 12;9(1):1738812
pubmed: 32313721
Front Immunol. 2018 Nov 01;9:2489
pubmed: 30455688
Acta Pharm Sin B. 2020 Dec;10(12):2272-2298
pubmed: 33354501
Blood. 2006 Mar 1;107(5):2013-21
pubmed: 16278308
Curr Opin Oncol. 2022 Mar 1;34(2):161-168
pubmed: 34930882
Cancer Immunol Immunother. 2012 Feb;61(2):289-293
pubmed: 22237887
Front Oncol. 2021 Oct 08;11:740642
pubmed: 34692519
J Immunol. 2020 Jul 1;205(1):223-236
pubmed: 32471881
Cancer Res. 2013 Feb 1;73(3):1063-75
pubmed: 23345163
Front Immunol. 2022 Mar 23;13:814627
pubmed: 35401570
Int J Cancer. 2013 Aug 1;133(3):771-8
pubmed: 23389942
Int J Mol Sci. 2022 Sep 27;23(19):
pubmed: 36232698
Front Immunol. 2013 Mar 06;4:59
pubmed: 23508732
Cancer Res. 2009 Apr 1;69(7):3077-85
pubmed: 19293190
Immunity. 2014 Nov 20;41(5):843-52
pubmed: 25517616
Cancer Immunol Res. 2023 May 3;11(5):558-569
pubmed: 36820825
Genome Biol. 2014;15(12):550
pubmed: 25516281
J Leukoc Biol. 2013 Mar;93(3):343-52
pubmed: 23136258
Nat Mater. 2023 May;22(5):644-655
pubmed: 36581770
PLoS Pathog. 2016 Dec 19;12(12):e1006115
pubmed: 27992577
Nature. 2018 Dec;564(7736):439-443
pubmed: 30405246
Oncoimmunology. 2022 Jan 27;11(1):2033433
pubmed: 35111387
Cancer J. 2010 Jul-Aug;16(4):399-403
pubmed: 20693853
Nat Commun. 2017 Oct 13;8(1):913
pubmed: 29030552
Nat Biotechnol. 2017 Apr 11;35(4):314-316
pubmed: 28398314
Cancers (Basel). 2019 Apr 03;11(4):
pubmed: 30987228
Nat Rev Immunol. 2015 Aug;15(8):471-85
pubmed: 26160613
N Engl J Med. 2021 Jun 10;384(23):2229-2240
pubmed: 34107182
J Leukoc Biol. 2021 Feb;109(2):283-285
pubmed: 32876957
Nat Rev Immunol. 2006 Nov;6(11):836-48
pubmed: 17063185
Biomedicines. 2022 Mar 08;10(3):
pubmed: 35327428
Nat Rev Mol Cell Biol. 2020 Sep;21(9):501-521
pubmed: 32424334
Front Immunol. 2017 Aug 23;8:1015
pubmed: 28878776
Immunology. 2009 Nov;128(3):439-50
pubmed: 20067543
Clin Exp Dermatol. 2021 Jan;46(1):28-33
pubmed: 32597504
J Clin Invest. 2012 Feb;122(2):575-85
pubmed: 22251703
Nature. 2017 Aug 24;548(7668):461-465
pubmed: 28738408
Nat Rev Immunol. 2015 Jul;15(7):405-14
pubmed: 26027717
Nature. 2017 Aug 24;548(7668):466-470
pubmed: 28759889
J Immunother. 2008 Jun;31(5):520-7
pubmed: 18463532
Nature. 2017 Sep 21;549(7672):394-398
pubmed: 28902841
J Leukoc Biol. 2004 Mar;75(3):504-14
pubmed: 14742635
Cells. 2022 Dec 16;11(24):
pubmed: 36552865
Cancer Discov. 2020 Jan;10(1):26-39
pubmed: 31852718
Clin Cancer Res. 2018 Apr 15;24(8):1805-1815
pubmed: 29358500
J Immunol. 2010 Jan 15;184(2):677-84
pubmed: 20018632
Front Immunol. 2019 Aug 07;10:1878
pubmed: 31440253
Immunol Rev. 2009 Jan;227(1):234-47
pubmed: 19120488
Br J Cancer. 2007 Jun 18;96(12):1879-87
pubmed: 17565341
Cancer Res. 2012 Oct 15;72(20):5188-97
pubmed: 22836755
Mol Cell. 2014 Apr 24;54(2):289-96
pubmed: 24766893
Front Immunol. 2019 Jun 11;10:1325
pubmed: 31244860
Cancer Res. 2003 Oct 1;63(19):6478-87
pubmed: 14559840
Nat Genet. 2003 Jul;34(3):267-73
pubmed: 12808457
Cancer Res. 2018 Apr 1;78(7):1685-1699
pubmed: 29363545
J Immunol. 2015 Jun 1;194(11):5174-86
pubmed: 25917094
Science. 2019 Mar 8;363(6431):
pubmed: 30846571
Immunity. 2014 Nov 20;41(5):830-42
pubmed: 25517615
Oncogene. 2003 May 19;22(20):3130-7
pubmed: 12789289
J Clin Oncol. 2022 Jan 10;40(2):127-137
pubmed: 34818112
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Cell. 2006 Feb 24;124(4):783-801
pubmed: 16497588
Int J Radiat Oncol Biol Phys. 2020 Sep 1;108(1):27-37
pubmed: 32339645
J Immunol. 2016 Mar 1;196(5):2004-9
pubmed: 26826244
Cell Res. 2019 Oct;29(10):846-861
pubmed: 31481761
Arch Oral Biol. 2018 Jun 5;93:141-148
pubmed: 29913322
J Clin Oncol. 2023 Oct 20;41(30):4794-4820
pubmed: 37579248
Cancer Immunol Res. 2019 Nov;7(11):1837-1848
pubmed: 31462408
Immunity. 2016 Nov 15;45(5):1093-1107
pubmed: 27793594
J Immunol. 2011 Mar 15;186(6):3364-72
pubmed: 21296980
Nat Immunol. 2014 Apr;15(4):323-32
pubmed: 24562310
Cells. 2020 Feb 11;9(2):
pubmed: 32054102
J Hepatol. 2013 Apr;58(4):743-9
pubmed: 23207140
Pathology. 2023 Mar;55(2):227-235
pubmed: 36639333
Oncoimmunology. 2018 Jan 15;7(4):e1419113
pubmed: 29632737
Nat Chem Biol. 2014 Dec;10(12):1043-8
pubmed: 25344812
Nat Rev Immunol. 2015 Feb;15(2):87-103
pubmed: 25614319
Clin Cancer Res. 2018 Jul 15;24(14):3299-3308
pubmed: 29618619
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Oncol Lett. 2018 Mar;15(3):3985-3990
pubmed: 29456743
Cancer Res. 2011 Nov 1;71(21):6561-6
pubmed: 22009534
Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):E7240-E7249
pubmed: 27799536
J Exp Med. 2007 Jan 22;204(1):105-15
pubmed: 17200410
Proc Natl Acad Sci U S A. 2015 Dec 15;112(50):15408-13
pubmed: 26607445
Eur J Cancer. 2022 Sep;173:285-296
pubmed: 35964471
Eur J Immunol. 2016 Jul;46(7):1615-21
pubmed: 27125983
Sci Signal. 2012 Mar 06;5(214):ra20
pubmed: 22394562
Immunol Cell Biol. 2018 Nov;96(10):1083-1094
pubmed: 29870118
Cancer Lett. 2013 Sep 1;337(2):184-92
pubmed: 23684927
Nat Rev Immunol. 2019 Nov;19(11):665-674
pubmed: 31570879
Cancers (Basel). 2020 Jul 28;12(8):
pubmed: 32731406
Science. 2018 Aug 17;361(6403):704-709
pubmed: 29976794
J Pathol. 2003 Jun;200(2):255-68
pubmed: 12754747
J Immunother Cancer. 2019 Sep 11;7(1):244
pubmed: 31511088
Cancer Immunol Res. 2019 Jan;7(1):12-28
pubmed: 30401679
F1000Res. 2017 Apr 10;6:456
pubmed: 28580131
Mol Cell. 2018 Sep 6;71(5):745-760.e5
pubmed: 30193098
Pigment Cell Melanoma Res. 2015 Sep;28(5):490-500
pubmed: 25818762
Arch Dermatol Res. 2009 Jan;301(1):83-6
pubmed: 18784932
Clin Cancer Res. 2007 May 15;13(10):2961-9
pubmed: 17504997
Lancet. 2022 Apr 30;399(10336):1718-1729
pubmed: 35367007
Immunity. 2019 Jan 15;50(1):37-50
pubmed: 30650380
Oncogene. 2009 Dec 3;28(48):4237-48
pubmed: 19734937
Immunology. 2018 May;154(1):3-20
pubmed: 29313948
Methods Mol Biol. 2011;677:127-47
pubmed: 20941607
J Biol Chem. 2009 Jul 3;284(27):18537-44
pubmed: 19419970
Oncoimmunology. 2014 Jan 1;3(1):e27402
pubmed: 24701375
Cancer Discov. 2019 Jan;9(1):34-45
pubmed: 30297358
Immunol Rev. 2010 Mar;234(1):142-62
pubmed: 20193017
Oncotarget. 2016 Mar 22;7(12):14064-82
pubmed: 26908442
J Invest Dermatol. 2012 Oct;132(10):2395-2406
pubmed: 22696054
J Clin Oncol. 2006 Dec 20;24(36):5716-24
pubmed: 17179105
Eur J Immunol. 2003 Apr;33(4):1052-62
pubmed: 12672071
Cancer Lett. 2022 Oct 1;545:215852
pubmed: 35926817
Int J Mol Sci. 2021 Apr 18;22(8):
pubmed: 33919546
Oncotarget. 2017 Jul 25;8(41):71249-71284
pubmed: 29050360